WuXi Biologics (02269) plummeted 5.66% during Tuesday's intraday trading session. The steep decline came after the company announced it would sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about $500 million.
The divestment move appears to be a preemptive measure ahead of potential U.S. legislation that could restrict business for Chinese biotech companies. The U.S. House of Representatives passed the Biosecure Act in September, which would ban federal contracts with targeted firms and their business partners.
With growing concerns over potential U.S. sanctions, investors have become wary of WuXi Biologics' future prospects, leading to the sharp sell-off in the company's shares on Tuesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。